Skye Bioscience (SKYE) to Host Oct 6 Conference Call at 8:00 a.m. ET

Skye Bioscience, Inc. (SKYE) announced it will host a conference call and live webcast to discuss a material event on October 6, 2025 at 8:00 a.m. ET.

Rhea-AI Filing Summary

Skye Bioscience, Inc. (SKYE) announced it will host a conference call and live webcast to discuss a material event on October 6, 2025 at 8:00 a.m. ET. The filing states that the information under Item 7.01, including Exhibit 99.1, is being furnished and expressly notes it is not being "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other SEC filings except by specific reference. No financial results, tables, transactions, or additional details are included in the disclosed text.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Skye Bioscience (SKYE) hold the conference call?

The conference call and webcast are scheduled for October 6, 2025 at 8:00 a.m. ET.

What exhibit accompanies the 8-K for SKYE?

Exhibit 99.1 is furnished with the Item 7.01 disclosure.

Is the information in Item 7.01 considered "filed" under the Exchange Act?

No. The disclosure states the information and Exhibit 99.1 are being furnished and are not being "filed" for purposes of Section 18 of the Exchange Act.

Does this 8-K include earnings or financial tables for SKYE?

No. The provided content contains no financial results, tables, or transaction details.

Will the webcast be accessible to the public?

The filing indicates a live webcast will be hosted, implying public access, but no access link or registration details are provided in the text.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/06/2025 - 08:18 AM EDT Learn about SEC filing dates

FALSE000151655100015165512025-10-062025-10-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 6, 2025

SKYE BIOSCIENCE, INC.

(Exact name of registrant as specified in its charter)

Nevada

000-55136

45-0692882

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification Number)

11250 El Camino Real, Suite 100, San Diego, CA 92130

(Address of principal executive offices)

(858) 410-0266

(Registrant’s telephone number, including area code)

_________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001

SKYE

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On October 6, 2025, Skye Bioscience, Inc. (the “Company”) issued a press release titled “Skye Bioscience Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial”. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The Company intends to host a conference call and live webcast to discuss the results on October 6, 2025 at 8:00 a.m. E.T. The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.						Description
99.1						Press Release, dated October 6, 2025
104						Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SKYE BIOSCIENCE, INC.
Dated: October 6, 2025			/s/  Punit Dhillon
			Name: Punit Dhillon
			Title: Chief Executive Officer